Equities research analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will announce ($0.23) earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for BioDelivery Sciences International’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.27). BioDelivery Sciences International posted earnings per share of $0.58 in the same quarter last year, which would suggest a negative year-over-year growth rate of 139.7%. The business is scheduled to issue its next quarterly earnings results on Monday, May 21st.
According to Zacks, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.90) to ($0.67). For the next year, analysts forecast that the business will post earnings of ($0.43) per share, with EPS estimates ranging from ($0.50) to ($0.39). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). The business had revenue of $12.51 million during the quarter, compared to analyst estimates of $9.83 million. BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%.
BDSI has been the subject of several analyst reports. HC Wainwright set a $4.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, April 13th. Cantor Fitzgerald restated a “buy” rating and set a $5.00 price objective on shares of BioDelivery Sciences International in a report on Thursday, March 15th. Seaport Global Securities initiated coverage on BioDelivery Sciences International in a report on Friday, January 26th. They set a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Wednesday, February 14th. Finally, ValuEngine downgraded BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average target price of $4.25.
In related news, Director Francis E. Odonnell, Jr. sold 113,876 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $2.14, for a total transaction of $243,694.64. Following the completion of the sale, the director now directly owns 319,717 shares of the company’s stock, valued at approximately $684,194.38. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 100,000 shares of the company’s stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $2.06, for a total transaction of $206,000.00. Following the sale, the director now directly owns 2,585,966 shares of the company’s stock, valued at $5,327,089.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 278,031 shares of company stock valued at $583,779. Insiders own 9.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its position in BioDelivery Sciences International by 138.2% during the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 20,599 shares during the period. JPMorgan Chase & Co. purchased a new stake in BioDelivery Sciences International during the 3rd quarter worth $116,000. Two Sigma Investments LP purchased a new stake in BioDelivery Sciences International during the 4th quarter worth $166,000. BlueCrest Capital Management Ltd purchased a new stake in BioDelivery Sciences International during the 4th quarter worth $201,000. Finally, Goldman Sachs Group Inc. purchased a new stake in BioDelivery Sciences International during the 4th quarter worth $223,000. 45.84% of the stock is owned by hedge funds and other institutional investors.
Shares of BDSI opened at $2.25 on Thursday. The company has a current ratio of 1.52, a quick ratio of 1.29 and a debt-to-equity ratio of 5.37. BioDelivery Sciences International has a fifty-two week low of $1.60 and a fifty-two week high of $3.60.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.